This paper reviews new treatments for atopic dermatitis that target the OX40-OX40L pathway, focusing on two drugs: rocatinlimab and amlitelimab. These medications work by blocking interactions between OX40 and OX40L, which are important in controlling inflammation in atopic dermatitis.

The authors reviewed clinical trials and scientific literature about OX40-OX40L inhibitors, particularly focusing on rocatinlimab and amlitelimab. They analyzed phase 1 and 2 clinical trials that tested these drugs in patients with atopic dermatitis.

The studies included: - Adults with moderate-to-severe atopic dermatitis who hadn't responded well to topical treatments - For rocatinlimab: 274 patients in a phase 2b trial - For amlitelimab: 89 patients with moderate-to-severe atopic dermatitis in a phase 2a trial - Some studies also included healthy volunteers for initial safety testing

Both medications showed promising

The authors conclude that OX40-OX40L inhibitors appear to be promising new treatments for atopic dermatitis. They may have a unique ability to modify the disease course since benefits continued even after stopping treatment. However, longer-term studies are still needed to fully understand their safety and effectiveness.